The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis
Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications London Roots Analysis has announced the addition of “ Fc Fusion Therapeutics Market , 2021-2030” report to its list of offerings. With 13 drugs approved in the European Union and the US, Fc fusion therapeutics are considered to be one of the most successful classes of IgG-based products. The success of these biopharmaceutical products can be attributed to their diverse biological and pharmacological properties, including an extended serum half-life, enhanced Fc mediated effector functions, easy expression, increased stability and aggregation resistance, modulated immunogenicity and improved safety profiles, for the treatment of a wide range of disease indications To order this 130+ page report, wh...